Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562665 | 0.90 | DPP4 (0.65) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3562721 | 0.88 | DPP4 (0.63) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3559132 | 0.88 | DPP4 (0.66) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3562534 | 0.87 | DPP4 (0.62) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3562797 | 0.87 | DPP4 (0.61) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3559403 | 0.86 | DPP4 (0.61) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3566252 | 0.86 | DPP4 (0.70) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL638550 | 0.85 | DPP4 (0.63) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL555626 | 0.84 | DPP4 (0.74) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL638127 | 0.81 | DPP4 (0.81) | DPP4CHRM1CHRM2CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838529-B2 | Xanthine derivates, their preparation and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20090131432-A1 | XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7495005-B2 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-02-24 | — | — | US | disclosed |
| EP-1554278-B1 | XANTHINE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1554278-A2 | XANTHINE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040166125-A1 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-26 | — | — | US | disclosed |
| WO-2004018467-A2 | PHENACYL XANTHINE DERIVATIVES AS DPP-IV INHIBITOR | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040166125-A1 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | XDH, CALCRL, CALCA | DPP4 55/4885CHRM1 117/4885CHRM2 180/4885 |
| US-20090131432-A1 | XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | XDH, CALCRL, GPR119 | DPP4 68/4885CHRM1 54/4885CHRM2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.